---
title: 'Clinical Daily Summary: What Happened on November 12, 2026'
headline: Lilly reports one-year Taltz-Zepbound results in psoriatic arthritis
description: The trial found higher response and weight-loss rates with the combination.
  A transplant microbiome analysis missed its primary endpoint, while researchers
  presented logic-gated cell therapies and Actinium opened enrollment in an imaging
  study.
url: https://thebench.bio/news/clinical/2026-11-12
topic: clinical
date: '2026-11-12'
covers:
- '2026-11-12'
date_published: '2026-11-12T12:02:23Z'
date_modified: '2026-11-12T12:02:23Z'
tags:
- Clinical
- Industry
sources: 4
publisher: TheBench.Bio
---

# Clinical Daily Summary: What Happened on November 12, 2026

**Lilly reports one-year Taltz-Zepbound results in psoriatic arthritis**

The trial found higher response and weight-loss rates with the combination. A transplant microbiome analysis missed its primary endpoint, while researchers presented logic-gated cell therapies and Actinium opened enrollment in an imaging study.

## Today in brief

Lilly’s 271-person psoriatic arthritis trial found higher rates of disease response and weight loss with Taltz plus Zepbound than with Taltz alone at one year. [1] In a transplant analysis, microbiome diversity at engraftment was not significantly linked to one-year non-relapse mortality, but baseline diversity was associated with survival outcomes. [2]

## Lilly reports higher response and weight-loss rates with combination

In the Phase IIIb TOGETHER-PsA trial, 39.2% of participants taking Taltz plus Zepbound had an ACR50 response and lost at least 10% of their body weight by week 52, compared with 1.7% taking Taltz alone. [1] ACR50 means at least a 50% improvement in disease signs and symptoms. [1]

At one year, 43.7% of the combination group had an ACR50 response, compared with 15.7% on Taltz alone. At least 10% weight loss occurred in 85.7% and 6.7%, respectively. [1] Minimal disease activity was reached by 28.2% of participants on the combination and 13.6% on Taltz alone. [1] These one-year results were exploratory. The trial’s primary endpoint was assessed at week 36. [1]

Reported adverse events were generally mild or moderate, with no unexpected safety signals reported. [1]

## Transplant analysis misses microbiome primary endpoint

An analysis of 304 transplant participants and 2,575 stool samples found no significant association between microbiome diversity around neutrophil engraftment and non-relapse mortality at one year. [2] The analysis missed its primary endpoint. Diversity at engraftment also showed no significant association with the other clinical outcomes examined. [2]

Participants with lower microbiome diversity at baseline had shorter overall survival and lower graft-versus-host disease-free, relapse-free survival. [2] Exploratory analyses found lower microbiome diversity and microbial load 14 to 28 days after transplant in the post-transplant cyclophosphamide group than in the tacrolimus and methotrexate group. [2]

## Also worth knowing

- At the Society for Immunotherapy of Cancer meeting, at least 10 abstracts described CAR T-cell or T-cell engager designs that use combinations of tumor antigens to control activation. A2 Biotherapeutics said a patient with KRAS G12V-mutant lung cancer remained well 12 months after a complete response to A2B694. [3]
- Actinium Pharmaceuticals began enrolling patients with advanced solid tumors in RADIANZ, an imaging study designed to guide development of its HER3-targeting radiotherapy ATNM-400. [4]

## The day in numbers

- **39.2% vs. 1.7%**: Share reaching both ACR50 response and at least 10% weight loss at week 52 with Taltz plus Zepbound versus Taltz alone. [1]
- **304 participants**: Number included in the transplant microbiome analysis. [2]

## Also published

- [STAT+: What to know about Biogen’s big lupus study readout](<https://www.statnews.com/2026/11/12/biogen-lupus-litifilimab-what-to-know/?utm_campaign=rss>), STAT Biotech
- [How Patients’ Use of AI Impact How Sponsors Communicate with Them](<https://www.pharmexec.com/view/patients-use-ai-impact-how-sponsors-communicate-with-them>), Pharmaceutical Executive
- [From phase 1 to phase 3: Scaling radiopharmaceutical trials](<https://pharmaphorum.com/rd/phase-1-phase-3-scaling-radiopharmaceutical-trials>), pharmaphorum
- [Life-extending peptides are likely not around the corner](<https://www.pharmaceutical-technology.com/news/life-extending-peptides-are-likely-not-around-the-corner/>), Pharmaceutical Technology

## Sources

1. [Lilly reports promising 52-week results from TOGETHER-PsA trial in PsA](<https://www.clinicaltrialsarena.com/news/lilly-promising-results-together-psa-trial/>), Clinical Trials Arena, 2026-11-12
2. [Effect of two common GVHD prophylaxis regimens on the gut microbiome in a randomized phase 3 trial](<https://www.nature.com/articles/s41591-026-04712-z>), Nature Medicine, 2026-11-12
3. [Applications for logic gating expand at SITC 2026](<https://www.biocentury.com/article/661568/applications-for-logic-gating-expand-at-sitc-2026?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-12
4. [Patient enrolment begins in Actinium’s RADIANZ solid tumour trial](<https://www.clinicaltrialsarena.com/news/patient-enrolment-begins-actiniums-radianz-trial/>), Clinical Trials Arena, 2026-11-12

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.clinicaltrialsarena.com/news/lilly-promising-results-together-psa-trial/>
[2]: <https://www.nature.com/articles/s41591-026-04712-z>
[3]: <https://www.biocentury.com/article/661568/applications-for-logic-gating-expand-at-sitc-2026?utm_source=bc_rss&utm_medium=rss>
[4]: <https://www.clinicaltrialsarena.com/news/patient-enrolment-begins-actiniums-radianz-trial/>
